Multi-omics Analysis Reveals Biomarkers that Contribute to Biological Age Rejuvenation in Response to Therapeutic Plasma Exchange

Matias Fuentealba,Dobri Kiprov,Kevin Schneider,Wei-Chieh Mu,Prasanna Ashok Kumaar,Herbert Kasler,Jordan B Burton,Mark Watson,Heather Halaweh,Christina D King,Zehra Stara Yuksel,Chelo Roska-Pamaong,Birgit Schilling,Eric Verdin,David Furman

DOI: https://doi.org/10.1101/2024.08.02.24310303

2024-08-08

Abstract:The rapid increase in the proportion of older adults worldwide poses a huge challenge for healthcare systems. Currently, age-related chronic diseases account for over 90% of annual healthcare expenditures (more than $4.1 trillion) in the US alone. Thus, new therapies to improve healthspan and reduce the burden of chronic disease are needed. Herein, we conducted a phase 3 controlled clinical trial to evaluate the biological age (BA) effects of different therapeutic plasma exchange (TPE) modalities in ambulatory individuals. We longitudinally profiled the subjects to measure changes in the epigenome, proteome, metabolome, glycome, and shifts in immune cell composition (cytomics). We demonstrate that administering TPE supplemented with intravenous immunoglobulin (IVIG) (TPE-IVIG) on a biweekly regime (two sessions in the first week, followed by a three-week break) is a robust therapy for BA rejuvenation. This intervention induced coordinated cellular and molecular omics responses, reversed age-related immune decline, and modulated key cellular senescence-associated proteins. Integrative analysis revealed baseline biomarkers associated with successful responses, indicating that TPE-IVIG treatment benefits those with a poorer baseline health status. In summary, this is the first multi-omics study to examine the effectiveness of various TPE modalities, which demonstrate biological age rejuvenation and the molecular features associated with this rejuvenation.

Pharmacology and Therapeutics

What problem does this paper attempt to address?

The problem this paper attempts to address is the evaluation of the impact of different therapeutic plasma exchange (TPE) regimens on biological age (BA) and the identification of biomarkers associated with rejuvenation of biological age through multi-omics analysis. Specifically, the researchers conducted a phase 3 clinical trial to assess the effects of three different TPE regimens (once a month, once every 2 weeks, and once every 2 weeks combined with intravenous immunoglobulin (IVIG)) on improving health status and reducing the burden of chronic diseases.

### Main Issues:
1. **Evaluating the Effectiveness of TPE**: The researchers aim to reverse or slow down the increase in biological age through TPE treatment, thereby improving the health status of the elderly.
2. **Identifying Biomarkers**: Through multi-omics analysis (including epigenomics, proteomics, metabolomics, glycomics, and cytomics), identify biomarkers associated with rejuvenation of biological age after TPE treatment.
3. **Predicting Treatment Response**: Determine which baseline characteristics (such as clinical indicators and omics features) can predict an individual's response to TPE treatment, particularly who might benefit the most from the treatment.

### Research Background:
- **Global Aging Challenge**: The proportion of the elderly population is increasing globally, leading to a heavier burden of chronic diseases and immense pressure on healthcare systems.
- **Concept of Biological Age**: Biological age refers to the actual age of an individual's physiological state, influenced by various factors such as lifestyle, genetics, and environment.
- **Existing Interventions**: Previous studies have shown that lifestyle interventions (such as diet and exercise) and pharmacological interventions (such as metformin) can slow down the increase in biological age.

### Research Methods:
- **Clinical Trial Design**: 30 participants were randomly assigned to four groups (once a month TPE, once every 2 weeks TPE, once every 2 weeks TPE combined with IVIG, control group) and underwent a 3-month treatment.
- **Multi-omics Analysis**: Blood samples from participants were collected and analyzed for epigenomics, proteomics, metabolomics, glycomics, and cytomics.
- **Biological Age Assessment**: Changes in biological age were assessed using 35 different epigenetic clocks.

### Main Findings:
- **Best Effect of TPE + IVIG**: The TPE combined with IVIG treatment every 2 weeks showed the most significant rejuvenation effect on biological age, with an average reduction of 2.61 years.
- **Restoration of the Immune System**: TPE + IVIG treatment significantly restored age-related changes in immune cell composition, particularly increasing the proportion of CD8 and CD4 naive T cells and decreasing the proportion of NK cells and monocytes.
- **Predictive Value of Baseline Characteristics**: High baseline levels of bilirubin, glucose, and alanine aminotransferase (ALT) were associated with greater rejuvenation effects on biological age, suggesting that individuals with poorer health status might benefit more from the treatment.

### Conclusion:
This study is the first to comprehensively evaluate the impact of different TPE regimens on biological age through multi-omics analysis, identifying biomarkers associated with rejuvenation of biological age, and highlighting the significant effect of TPE combined with IVIG treatment in reversing immune aging. These findings provide important scientific evidence for the development of new anti-aging therapies.